The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …

The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and
herpesviruses―code for a protease, which is indispensable for viral maturation and …

Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …